PriceTargets.com logo

CymaBay Therapeutics - CBAY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $32.50
  • Forecasted Upside: 0.06%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 11 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$32.48 As of 04/1/2024 01:00 AM ET
+0 (0.00%)
Get New CymaBay Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBAY

Analyst Price Target is $32.50
▲ +0.06% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $32.50, with a high forecast of $32.50 and a low forecast of $32.50. The average price target represents a 0.06% upside from the last price of $32.48.

This chart shows the closing price for CBAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in CymaBay Therapeutics. This rating has held steady since January 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2023
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/29/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$32.50
2/20/2024Leerink PartnersReiterated RatingOutperform ➝ Market Perform$32.50
2/14/2024Lifesci CapitalDowngradeOutperform ➝ Market Perform
2/14/2024Piper SandlerReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.50
2/14/2024UBS GroupReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.50
2/13/2024BTIG ResearchReiterated RatingBuy ➝ Neutral
2/13/2024JonestradingReiterated RatingBuy ➝ Hold
2/13/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral$32.50
2/13/2024B. RileyReiterated RatingBuy ➝ Neutral$29.00 ➝ $32.50
2/13/2024HC WainwrightDowngradeBuy ➝ Neutral
2/13/2024Raymond JamesDowngradeOutperform ➝ Market Perform$32.50
2/12/2024William BlairDowngradeOutperform ➝ Market Perform
12/26/2023Lifesci CapitalReiterated RatingOutperform
12/15/2023HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $28.00
11/14/2023William BlairReiterated RatingOutperform
11/8/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$23.00 ➝ $24.00
11/8/2023Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$33.00 ➝ $34.00
11/7/2023HC WainwrightBoost TargetBuy ➝ Buy$21.00 ➝ $24.00
11/6/2023Piper SandlerBoost TargetOverweight ➝ Overweight$19.00 ➝ $33.00
9/26/2023UBS GroupBoost TargetBuy ➝ Buy$18.00 ➝ $25.00
9/8/2023BTIG ResearchBoost TargetBuy ➝ Buy$22.00 ➝ $24.00
9/8/2023B. RileyBoost TargetBuy ➝ Buy$16.00 ➝ $22.00
9/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$21.00
9/7/2023Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$17.00 ➝ $33.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$15.00
8/15/2023JonestradingBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
8/14/2023HC WainwrightBoost Target$19.00 ➝ $21.00
8/14/2023UBS GroupInitiated CoverageBuy$18.00
8/11/2023BTIG ResearchBoost TargetBuy ➝ Buy$18.00 ➝ $22.00
8/11/2023GuggenheimInitiated CoverageBuy$20.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$19.00
8/1/2023HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $19.00
7/31/2023B. RileyBoost TargetBuy$8.00 ➝ $16.00
7/4/2023BTIG ResearchBoost Target$15.00 ➝ $18.00
5/16/2023Cantor FitzgeraldBoost Target$13.00 ➝ $15.00
4/5/2023William BlairInitiated CoverageOutperform
3/17/2023HC WainwrightBoost Target$10.00 ➝ $12.00
3/9/2023BTIG ResearchInitiated CoverageBuy$15.00
3/7/2023OppenheimerBoost TargetOutperform$10.00 ➝ $12.00
2/8/2023Leerink PartnersBoost TargetOutperform$10.00 ➝ $12.00
1/31/2023Cantor FitzgeraldBoost TargetOverweight$10.00 ➝ $13.00
1/29/2023Piper SandlerBoost TargetOverweight$12.00 ➝ $19.00
1/17/2023Raymond JamesBoost TargetStrong-Buy$14.00 ➝ $17.00
11/17/2022OppenheimerLower Target$10.00
5/18/2022B. RileyLower TargetBuy$10.00 ➝ $8.00
5/16/2022OppenheimerLower TargetNA$12.00
5/16/2022HC WainwrightLower TargetNA$12.00 ➝ $10.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
11/11/2021Raymond JamesBoost TargetStrong-Buy$12.00 ➝ $14.00
8/18/2021B. RileyLower TargetBuy$13.00 ➝ $10.00
8/15/2021Leerink PartnersReiterated RatingBuy$10.00
8/3/2021HC WainwrightLower TargetBuy$13.00 ➝ $12.00
6/21/2021JonestradingReiterated RatingBuy$8.00
6/14/2021JonestradingInitiated CoverageBuy$8.00
5/18/2021Leerink PartnersReiterated RatingBuy$10.00
3/31/2021Cantor FitzgeraldLower TargetHold ➝ Overweight$20.00 ➝ $7.00
3/9/2021Piper SandlerReiterated RatingBuy$12.00
11/30/2020Smith Barney CitigroupBoost Target$9.00 ➝ $10.00
11/6/2020Raymond JamesBoost TargetStrong-Buy$11.00 ➝ $12.00
11/6/2020Leerink PartnersBoost TargetOutperform$8.00 ➝ $10.00
10/9/2020Cantor FitzgeraldReiterated RatingOverweight
9/29/2020Lifesci CapitalReiterated RatingOutperform
9/10/2020OppenheimerReiterated RatingBuy$14.00
9/9/2020B. RileyBoost Target$9.00 ➝ $13.00
8/25/2020CitigroupBoost TargetBuy$7.00 ➝ $9.00
8/12/2020B. RileyReiterated RatingBuy$9.00
8/11/2020Raymond JamesBoost TargetStrong-Buy$10.00 ➝ $11.00
8/4/2020Cantor FitzgeraldBoost TargetOverweight$15.00 ➝ $20.00
8/4/2020HC WainwrightBoost TargetBuy$9.00 ➝ $13.00
8/4/2020B. RileyReiterated RatingBuy$9.00
8/3/2020OppenheimerInitiated CoverageBuy$12.00
8/3/2020Stifel NicolausBoost TargetHold ➝ Buy$8.00 ➝ $13.00
7/30/2020Piper SandlerInitiated CoverageOverweight$12.00
7/23/2020OppenheimerBoost TargetHold ➝ Outperform$6.00 ➝ $10.00
7/23/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy
6/22/2020B. RileyReiterated RatingBuy$6.00
5/26/2020HC WainwrightUpgradeNeutral ➝ Buy$9.00
5/15/2020CitigroupBoost TargetBuy$1.60 ➝ $7.00
5/12/2020B. RileyUpgradeNeutral ➝ Buy$1.50 ➝ $6.00
5/12/2020Roth CapitalUpgradeNeutral ➝ Buy$15.00
5/12/2020Cantor FitzgeraldBoost TargetHold ➝ Overweight$5.00 ➝ $15.00
5/12/2020Leerink PartnersUpgradeMarket Perform ➝ Outperform$2.50 ➝ $6.00
5/12/2020Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $8.00
5/12/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$7.00
5/12/2020Evercore ISIUpgradeIn-Line ➝ Outperform$15.00
3/20/2020CitigroupLower TargetBuy$2.00 ➝ $1.60
3/18/2020B. RileyLower TargetNeutral$2.00 ➝ $1.50
3/13/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$2.00 ➝ $5.00
3/12/2020OppenheimerUpgradeMarket Perform ➝ Buy$4.00
1/30/2020HC WainwrightReiterated RatingHold
1/2/2020Leerink PartnersReiterated RatingMarket Perform
12/20/2019HC WainwrightReiterated RatingNeutral
11/27/2019B. RileyReiterated RatingHold$2.00
11/26/2019Roth CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $2.00
11/26/2019HC WainwrightDowngradeBuy ➝ Neutral$16.00 ➝ $2.00
11/26/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$20.00 ➝ $2.00
11/26/2019Raymond JamesDowngradeStrong-Buy ➝ Market Perform
11/25/2019OppenheimerDowngradeOutperform ➝ Hold
11/25/2019SunTrust BanksDowngradeBuy ➝ Hold
11/25/2019Stifel NicolausDowngradeBuy ➝ Hold$4.00
11/24/2019Evercore ISIReiterated RatingBuy$12.00
(Data available from 11/15/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
CymaBay Therapeutics logo
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $32.48
Low: $32.48
High: $32.48

50 Day Range

MA: $32.44
Low: $32.18
High: $32.48

52 Week Range

Now: $32.48
Low: $7.26
High: $32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

The following Wall Street sell-side analysts have issued research reports on CymaBay Therapeutics in the last twelve months: B. Riley, BTIG Research, Cantor Fitzgerald, HC Wainwright, Jonestrading, Leerink Partners, Lifesci Capital, Piper Sandler, Raymond James, StockNews.com, UBS Group AG, and William Blair.
View the latest analyst ratings for CBAY.

What is the current price target for CymaBay Therapeutics?

0 Wall Street analysts have set twelve-month price targets for CymaBay Therapeutics in the last year. Their average twelve-month price target is $32.50, suggesting a possible upside of 0.1%. UBS Group AG has the highest price target set, predicting CBAY will reach $32.50 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $32.50 for CymaBay Therapeutics in the next year.
View the latest price targets for CBAY.

What is the current consensus analyst rating for CymaBay Therapeutics?

CymaBay Therapeutics currently has 11 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CBAY, but not buy more shares or sell existing shares.
View the latest ratings for CBAY.

What other companies compete with CymaBay Therapeutics?

Other companies that are similar to CymaBay Therapeutics include Mirum Pharmaceuticals, Pandion Therapeutics, Avid Bioservices, Urovant Sciences and Rigel Pharmaceuticals. Learn More about companies similar to CymaBay Therapeutics.

How do I contact CymaBay Therapeutics' investor relations team?

CymaBay Therapeutics' physical mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (510) 293-8800 and its investor relations email address is [email protected]. The official website for CymaBay Therapeutics is www.cymabay.com. Learn More about contacing CymaBay Therapeutics investor relations.